TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer

Author:

Agarwal Neeraj1ORCID,Saad Fred2,Azad Arun A3ORCID,Mateo Joaquin4,Matsubara Nobuaki5ORCID,Shore Neal D6ORCID,Chakrabarti Jayeta7,Chen Hsiang-Chun8,Lanzalone Silvana9,Niyazov Alexander10,Fizazi Karim11

Affiliation:

1. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA

2. University of Montréal Hospital Center, Montréal, Québec, H2L 4M1, Canada

3. Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia

4. Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain

5. National Cancer Center Hospital East, Chiba, 277-8577, Japan

6. Carolina Urologic Research Center, Myrtle Beach, SC 29572, USA

7. Pfizer Ltd., Tadworth, Surrey, KT20 7NS, UK

8. Pfizer Inc., La Jolla, CA 92121, USA

9. Pfizer Oncology, Milan, 20152, Italy

10. Pfizer Inc., New York, NY, 10012, USA

11. Institut Gustave Roussy, University of Paris Sud, Villejuif, 94800, France

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors in combination with androgen-receptor signaling inhibitors are a promising therapeutic option for patients with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations. Here, we describe the design and rationale of the multinational, phase III, TALAPRO-3 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide in patients with mCSPC and HRR gene alterations. The primary end point is investigator-assessed radiographic progression-free survival (rPFS) per RECIST 1.1 in soft tissue, or per PCWG3 criteria in bone. The TALAPRO-3 study will demonstrate whether the addition of talazoparib can improve the efficacy of enzalutamide as assessed by rPFS in patients with mCSPC and HRR gene alterations undergoing androgen deprivation therapy. Clinical Trial Registration: NCT04821622 ( ClinicalTrials.gov ) Registry Name: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC. Date of Registration: 29 March 2021.

Funder

Pfizer

Astellas Pharma

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Reference54 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3